What it does
Charta Tech, now presented through Charta Health, uses AI to review clinical charts before billing. It supports autonomous coding, revenue discovery, payer compliance, clinical quality and risk adjustment. The SPC profile describes AI chart review for every encounter; the current homepage positions the platform for provider organizations, health systems, payers and MSOs.
The fit is a healthcare organization that wants broader pre-bill review without adding a large manual coding team. Charta’s value is in finding unsupported codes, documentation gaps and missed revenue while the chart is still open, but the system also has to preserve clinical judgment, auditability and payer-specific compliance.
Why I’d look closer
The public product surface is concrete. Charta says it reviews every note after submission, links recommendations to documentation, and gives clinical leaders feedback on quality measures and care gaps. Its homepage reports an 11% revenue uplift claim and the clinical-documentation page shows customer claims of 90% increases in pre-bill chart-review coverage. Those are company-reported/customer-selected outcomes, not independent measurements.
The founder context fits the infrastructure problem. The SPC profile describes Justin Liu with Rockset growth, Google Cloud Security and UC Berkeley computer-science/business experience, and Scott Morris with Rockset product-engineering experience. The current About page names a clinical officer and describes custom integrations for each stakeholder.
What I’d ask
What is the reviewer’s role when Charta’s suggested code or compliance finding conflicts with a clinician or payer rule? I’d request a sample chart audit trail, evidence citations, false-positive handling, coding policy updates, security/BAA materials and a comparison against the organization’s existing pre-bill review. The product should reduce rework without turning a revenue target into unsupported coding.
My editorial take
Charta is a strong fit for provider organizations with measurable coding leakage or limited pre-bill review capacity. The product has a specific workflow and public implementation surface. I’d judge it on defensible chart-level evidence and denial reduction, keeping the uplift claims company-reported.
Quick facts
| Field | Sourced detail |
|---|---|
| Buyer fit | Providers, health systems, payers, MSOs and revenue-cycle teams |
| Workflow | Pre-bill coding, revenue discovery, compliance, quality and risk adjustment |
| Proof signal | Company/customer claims around 11% uplift and 90% review-coverage increase |
| Public pricing | Not exposed in the sources checked |
Sources checked
Checked 2026-09-19.
| Source | Used for |
|---|---|
| SPC company profile | Product and founder context |
| Charta Health homepage | Current product, buyer segments and company-reported outcomes |
| Clinical documentation improvement | Workflow and customer-claim context |
| About Charta | Leadership and company context |
